Cyclerion Therapeutics, Inc. (CYCN) financial statements and ratios from SEC XBRL: revenue $2.07M (TTM), net margin -170.1%, revenue growth 3.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.07M |
| Net Margin | -170.1% |
| Revenue Growth (YoY) | 3.7% |
| EPS Growth (YoY) | -8.3% |
| Price / Book | 3.58 |
| Price / Sales | 20.81 |
| FCF Yield | -28.3% |
| Altman Z-Score | -27.76 (distress) |
| Sector P/E (Healthcare) | 21.7 |
CYCN overview · CYCN earnings · CYCN KPIs · CYCN investor relations · CYCN ownership · CYCN peers · CYCN filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.